Close Menu
Trade Verdict
  • Home
  • Latest News
  • Investing
  • Personal Finance
  • Retirement
  • Economy
  • Stocks
  • Bonds
  • Commodities
  • Cryptocurrencies
Facebook X (Twitter) Instagram
Trade Verdict
  • Latest News
  • Investing
  • Personal Finance
  • Retirement
  • Economy
Facebook X (Twitter) Instagram
Trade Verdict
Latest News

NovaBay Prescribed drugs, Inc. (NBY) Declares $0.80 Particular Dividend, Boosting Shareholder Worth

EditorialBy EditorialSeptember 25, 2025No Comments2 Mins Read

[ad_1]

On this article, we might be having a look on the 15 Finest Biotech Penny Shares to Spend money on Proper Now. NovaBay Prescribed drugs, Inc. is one in every of them.

NovaBay Prescribed drugs, Inc. (NYSE:NBY) is a biopharmaceutical firm specializing in anti-infective therapies for irritation and infection-related situations. Its flagship product, Avenova, is an antimicrobial lid and lash cleanser clinically confirmed to alleviate power eye situations by eradicating microorganisms and particles. The corporate additionally develops hypochlorous acid-based wound care options, providing protected and efficient remedies for pores and skin and wound infections.

In September 2025, NovaBay Prescribed drugs, Inc. (NYSE:NBY) introduced a one-time particular money dividend of $0.80 per share, payable on September 29 to shareholders of report as of September 15. The dividend represents greater than 25% of the present inventory worth, prompting a market notification from the NYSE concerning potential worth affect. This transfer underscores the company’s robust money place and dedication to returning worth to shareholders, highlighting monetary stability amid ongoing operations.

NovaBay Pharmaceuticals, Inc. (NBY) Declares $0.80 Special Dividend, Boosting Shareholder Value
NovaBay Prescribed drugs, Inc. (NBY) Declares $0.80 Particular Dividend, Boosting Shareholder Worth

Though there have been no new product approvals or launches this month, NovaBay Prescribed drugs, Inc. (NYSE:NBY) continues to give attention to its established antimicrobial and eye care portfolio, which maintains strong market efficiency. The particular dividend, alongside the upcoming 2025 annual assembly, reinforces investor confidence and the enterprise’s place as a lovely biotech penny inventory. This monetary sign suggests potential for continued profitability and powerful money circulation sooner or later.

Whereas we acknowledge the potential of NBY as an funding, we consider sure AI shares provide higher upside potential and carry much less draw back threat. If you happen to’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.

READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase NOW 

Disclosure: None.

[ad_2]

Editorial
  • Website

Related Posts

Free streaming service Tubi is rivaling main gamers for viewership

December 24, 2025

This one Costco merchandise has skyrocketed 108% in value over simply 2 years. Now the retail large is proscribing purchases

December 24, 2025

Janus Henderson discloses 1.89% stake in Avadel Prescribed drugs

December 24, 2025

Novo’s Wegovy tablet is deliberate to enter U.S. self-pay channels, Reuters says

December 24, 2025
Add A Comment
Leave A Reply Cancel Reply

Trade Verdict
Facebook X (Twitter) Instagram Pinterest
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Service
© 2026 Trade Verdict. All rights reserved by Trade Verdict.

Type above and press Enter to search. Press Esc to cancel.